SLC5A2 and type 2 diabetes mellitus: Early indications of potential SGLT2 inhibitor benefits on kidney function camefrom CV safety trials undertaken in patients with T2D (ie, with canagliflozin,dapagliflozin, and empagliflozin in the CANVAS, DECLARE-TIMI 58, and EMPA-REGOUTCOMES trials, respectively).